Eisai’s 2008 Eribulin NDA Plan Foiled; Beaten To The Punch By Ixempra
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has dealt a setback to Eisai's burgeoning oncology pipeline by denying the company's efforts to seek accelerated approval for its microtubule growth suppressor E7389 (eribulin mesylate)